Omnicell traded at $37.15 this Tuesday August 4th, decreasing $0.50 or 1.33 percent since the previous trading session. Looking back, over the last four weeks, Omnicell lost 17.88 percent. Over the last 12 months, its price rose by 21.80 percent. Looking ahead, we forecast Omnicell to be priced at 34.62 by the end of this quarter and at 32.46 in one year, according to Trading Economics global macro models projections and analysts expectations.
Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming the pharmacy care delivery model through automation designed to replace manual, error-prone processes, combined with a single, cloud-based platform and advanced services offerings. Its point-of-care automation solutions are designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Company's Omnicell Interface Software provides interface and integration between its medication-use products or its supply products and a healthcare facility’s in-house information management systems. Its Central Pharmacy IV Compounding Service offers a comprehensive service model inclusive of IV robotic technology, data analytic tools, and clinical support for insourced sterile compounding programs.